Europe Alopecia Market Research Report – Segmented By Disease, Treatment, Gender, Sales channel, End Use, & Country (UK, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands, Turkey, Czech Republic & Rest of Europe) - Industry Analysis on Size, Share, Trends, COVID-19 Impact & Growth Forecast | 2024 to 2029

Updated On: June, 2024
ID: 12203
Pages: 100

Europe Alopecia Market Size (2022 to 2027)

The Europe Alopecia Market was worth USD 2.65 billion in 2022 and is estimated to be growing at a CAGR of 7.96%, to reach USD 3.89 billion by 2027.

Alopecia is a medical condition that refers to sudden, excessive hair loss on the head area, mostly in circular patches. One such type of alopecia - Alopecia areata is a common autoimmune disease that causes baldness that results in partial or complete hair loss

Due to an increase in the prevalence of alopecia conditions such as androgenic alopecia, alopecia areata, alopecia totalis, and others, as well as an increase in the prevalence of chemotherapy-induced alopecia, the European alopecia market is expected to grow significantly during the forecast period. High levels of stress, hormonal imbalance, an increase in the usage of alcohol and cigarettes, and a shift in eating patterns all contribute to the market's growth. The ability of hair renewal is enhanced by cytokine therapy, which causes hair follicle cells to differentiate and proliferate while managing the hair growth cycle. Combination therapy has also been shown to be clinically effective in the treatment of alopecia. Combination therapies are now the most often used hair loss treatment.

The Europe alopecia treatment market is projected to be hampered by the patent expiration of many blockbuster medications and the adverse effects associated with existing hair loss treatment techniques. The increasing demand for hair loss treatment pharmaceuticals with improved effectiveness and low side effects is propelling the European alopecia market forward. For example, cytokine therapy and regenerative cell therapy have become increasingly popular in recent years for the treatment of various kinds of alopecia.

Changing lifestyle patterns, an increase in the frequency of autoimmune diseases, high levels of alcohol and smoking, and an aging population are all contributing to the growth of the Europe alopecia treatment market. Increased personal care spending and customer knowledge of hair growth product quality are also critical for the French market's growth. As a result, these factors are expected to fuel the expansion of the European alopecia (hair loss) market over the forecast period. In the coming years, the global androgenetic alopecia therapy market is likely to be driven by an increase in demand for surgical hair transplants.

Other significant reasons boosting the market include an increase in people's disposable money, technological developments in hair treatment medical equipment, and a growing emphasis on looking beautiful. Additionally, the ease of availability of scalp therapy is strengthening the industry.

However, The Europe alopecia treatment market is projected to be hampered by the patent expiration of many blockbuster medications and the adverse effects associated with existing hair loss treatment techniques.

This research report on the European alopecia market has been segmented and sub-segmented into the following categories:

By Disease Type:

  • Alopecia Areata
    • Male
    • Female
  • Cicatricial Alopecia
    • Male
    • Female
  • Traction Alopecia
    • Male
    • Female
  • Alopecia Totalis
    • Male
    • Female
  • Alopecia Universalis
    • Male
    • Female
  • Androgenetic Alopecia
    • Male
    • Female
  • Others
    • Male
    • Female

By Treatment:

  • Pharmaceuticals
  • Devices

By Gender:

  • Male
  • Female

By Sales Channel:

  • Prescriptions
  • OTC

By End Use:

  • Homecare Settings
  • Dermatology Clinics

By Country:

  • United Kingdom
  • France
  • Spain
  • Germany
  • Italy
  • Russia
  • Sweden
  • Denmark
  • Switzerland
  • Netherlands and
  • Rest of Europe

Medical diseases such as hyperthyroidism and cancer are the most common causes of alopecia. Every year, the incidence of cancer in the United Kingdom rises. Consumers in Germany are very concerned about their personal appearance and maintenance, and they spend a lot of money on things like hair care. Baldness, on the other hand, is a big problem in the country. According to the German Medical Group, men in Germany are opting for hair transplantation as a result of the rising problem of baldness and hair loss. As a result, these factors are expected to play a key role in driving the alopecia (hair loss) treatment market in Europe during the next several years. In some areas, hair loss has become a frequent problem.

Some countries, such as Germany and France, have a high prevalence of male pattern baldness. As a result, male consumers in the region have a strong demand for hair loss therapy solutions. Furthermore, the region's hair loss treatment goods are driven by an aging population and a shift in lifestyle. Due to the increased demand for these products in the country, the market's leading companies are expanding their facilities and product portfolios in Germany in order to stay competitive.


Johnson & Johnson, Inc., Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Cipla Ltd., Cellmid Ltd., The Himalaya Drug Company, Taisho Pharmaceutical Holdings Co., Ltd, Shiseido Co., Ltd and Zhangguang 101 Science & Technology Co., Ltd are a few of the noteworthy companies in the Europe alopecia treatment market.

Please wait. . . . Your request is being processed

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 1400

Didn’t find what you’re looking for?

Need something within your budget?


Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us: [email protected]

Click for Request Sample